Cambium Bio (ASX:CMB) Other Financing: A$-0.27 Mil (TTM As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Other Financing?

Cambium Bio ASX:CMB -6.74% 35 Other Financing is A$-0.27 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's Other Financing for the six months ended in Dec. 2025 was A$-0.06 Mil.

Cambium Bio's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.27 Mil.

Cambium Bio Other Financing Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Other Financing Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.17 0.40 0.00 0.00

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.21 -0.21 -0.06
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of A$-0.27 Mil mean?
Cambium Bio (ASX:CMB) has a Other Financing of A$-0.27 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cambium Bio and its competitors.
Is Cambium Bio's Other Financing too high?
Cambium Bio's current Other Financing is A$-0.27 Mil. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Other Financing compare to VRTX and REGN?
Cambium Bio's Other Financing of A$-0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Cambium Bio and its competitors. Cambium Bio's current Other Financing is A$-0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Other Financing of A$-0.27 Mil. The current Other Financing is A$-0.27 Mil. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Other Financing is A$-0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price